Resveratrol often displays hormesis-like biphasic dose responses. This occurs in a broad range of biological models and for numerous endpoints of biomedical interest and public health concern. Recognition of the widespread occurrence of the hormetic nature of many of the responses of resveratrol is important on multiple levels. It can help optimize study design protocols by investigators, create a dose-response framework for better addressing dose-related biological complexities and assist in the development of public health and medical guidance with respect to considerations for what is an optimal dose not just for an agent such as resveratrol, but also for the plethora of agents that also act via hormetic mechanisms.
Espin JC, Garcia-Conesa MT, and Tomas-Barberan FANutraceuticals: facts and fiction. Phytochemistry2007; 68: 2986-3008.
2.
Calabrese EJ , Mattson MP, and Calabrese V.Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exper Toxicol2010; 29: 980-1015.
3.
Seward ZM (30 November 2006). Quest for youth drives craze for ‘wine’ pills. The Wall Street Journal, http://www.post-gazette.com/pg/06334/742471-114.stm
4.
Das DKCommentary on ‘Resveratrol commonly displays hormesis: Occurrence and biomedical significance’ by Calabrese et al. Hum Exper Toxicol2010; 29: 1016-1017.
5.
De La Lastra CACommentary on ‘Resveratrol commonly displays hormesis: Occurrence and biomedical significance’ by Calabrese et al. Hum Exper Toxicol2010; 29: 1021-1023.
6.
Hayes DPCommentary on ‘Resveratrol commonly displays hormesis: Occurrence and biomedical significance’ by Calabrese et al. Hum Exper Toxicol2010; 29; 1018-1020.
7.
Lindsay DGCommentary on ‘Resveratrol commonly displays hormesis: Occurrence and biomedical significance’ by Calabrese et al. Hum Exper Toxicol2010; 29: 1024-1025.
8.
Marques FZ, Morris BJCommentary on ‘Resveratrol and Hormesis: Resveratrol - a hormetic marvel in waiting?Hum Exper Toxicol2010; 29: 1026-1028.
9.
Tedesco I., Russo M., and Russo GLCommentary on ‘‘Resveratrol commonly displays hormesis: occurrence and biomedical significance’’. Hum Exper Toxicol2010; 29: 1029-1031.
10.
Young JF, Bhattacharya S.Commentary on ‘‘Resveratrol commonly displays hormesis: occurrence and biomedical significance’’. Hum Exper Toxicol2010; 29: 1032-1033.
11.
Mukherjee S. , Dudley JI, and Das DKDose-dependency of resveratrol in providing health benefits. Dose Response2010 (in press).
12.
Calabrese EJHistorical blunders: how toxicology got the dose-response relationship half right. Cell Mol Biol2005; 51: 643-654.
13.
Calabrese EJGetting the dose response wrong. Why hormesis became marginalized and the threshold model accepted. Arch Toxicol2009a; 83: 227-247.
14.
Calabrese EJThe road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch Toxicol2009b; 83: 203-225.
15.
Calabrese EJ, Baldwin LAThe frequency of U-shaped dose-responses in the toxicological literature. Tox Sci2001; 62: 330-338.
16.
Calabrese EJ, Baldwin LAThe hormetic dose response model is more common than the threshold model in toxicology. Tox Sci2003a; 71: 246-250.
17.
Calabrese EJ, Baldwin LAToxicology rethinks its central belief-hormesis demands a reappraisal of the way risks are assessed. Nature2003b; 421: 691-692.
18.
Calabrese EJ, Blain R.The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol2005; 202: 289-301.
19.
Calabrese EJ , Staudenmayer JW, Stanek EJ, and Hoffmann GRHormesis outperforms threshold model in NCI anti-tumor drug screening data. Toxicol Sci2006; 94: 368-378.
20.
Calabrese EJ , Stanek III EJ, Nascarella MA, and Hoffmann GRHormesis predicts low-dose responses better than threshold models. Int J Toxicol2008; 27: 369-378.
